EP Patent
EP2327706A1 — Polymorphous forms III and IV of N-benzoyl-staurosporine
Assigned to Novartis AG · Expires 2011-06-01 · 15y expired
What this patent protects
The present invention relates to a crystalline form III and a crystalline form IV of N-benzoyl staurosporine.
USPTO Abstract
The present invention relates to a crystalline form III and a crystalline form IV of N-benzoyl staurosporine.
Drugs covered by this patent
- Rydapt (MIDOSTAURIN) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.